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Association of RosaceaWith Risk for Glioma
in a Danish Nationwide Cohort Study
Alexander Egeberg, MD, PhD; Peter R. Hansen, MD, PhD, DMSci; Gunnar H. Gislason, MD, PhD; Jacob P. Thyssen, MD, PhD, DMSci
IMPORTANCE Rosacea, a common facial skin disorder, has a poorly understood pathogenesis
in which increasedmatrix metalloproteinase activity might play an important role. Glioma
accounts for 80% of all primary malignant tumors in the central nervous system, and these
tumors also show upregulation of certain matrix metalloproteinases.
OBJECTIVE To investigate the association between rosacea and the risk for glioma.
DESIGN, SETTING, AND PARTICIPANTS Nationwide cohort study of the Danish population from
individual-level linkage of administrative registers. All Danish citizens 18 years or older from
January 1, 1997, to December 31, 2011, were eligible for inclusion. A total of 5 484910
individuals were eligible for analysis; of these, 68 372 had rosacea and 5 416 538 constituted
the reference population. Data were analyzed from July 14 to August 10, 2015.
MAIN OUTCOMES ANDMEASURES The outcome of interest was a diagnosis of glioma.
Incidence rates per 10000 person-years were calculated, and incidence rate ratios adjusted
for age, sex, and socioeconomic status were estimated by Poisson regression distribution
models.
RESULTS Of the 5 484910 individuals in the study population, 21 118 individuals developed
glioma during the study period, including 20934 of the 5 416 538 individuals in the reference
population (50.4%women; mean [SD] age, 40.8 [19.7] years) and 184 of the 68 372 patients
with rosacea (67.3%women; mean [SD] age, 42.2 [16.5] years). The incidence rate (95% CI)
of glioma was 3.34 (3.30-3.39) in the reference population and 4.99 (4.32-5.76) in patients
with rosacea. The adjusted incidence rate ratio (95% CI) of glioma in patients with rosacea
was 1.36 (1.18-1.58) in our primary analysis. When analyses were limited to patients with a
primary diagnosis of rosacea by a hospital dermatologist (n = 5964), the adjusted incidence
rate ratio was 1.82 (1.16-2.86).
CONCLUSIONS AND RELEVANCE Rosacea was associated with a significantly increased risk for
glioma in a nationwide cohort. This associationmay bemediated, in part, by mechanisms
dependent onmatrix metalloproteinases. Increased focus on neurologic symptoms in
patients with rosaceamay be warranted.
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R osacea is a common chronic inflammatory skin condi-tion characterized primarily by transient or persistentcentrofacial erythema with concomitant telangiec-
tasia, papules, and pustules.1 Several subtypes of rosacea
exist, and these subtypes often overlap in the same patient.
Neurogenic rosacea is characterized by neurologic or neuro-
psychiatric symptoms, such as complex regional pain
syndrome, depression, essential tremor, and obsessive-
compulsive disorder, which suggest cerebral involvement.2,3
Asignificantrelationshipbetweenrosaceaandmigrainehasalso
beenestablished, further indicatinga relationshipbetween ro-
saceaandthebrain.4Matrixmetalloproteinases (MMPs)areen-
zymes that are involved in tissue remodeling, organ develop-
ment, and regulation of inflammatory processes. Increased
activation and expression of certain MMPs in skin with rosa-
cea, in particular in ocular and phymatous rosacea, have been
identifiedpreviously.1,5 IncreasedexpressionofMMPshasalso
been associated with neuroinflammation and gliomas.6,7 Ma-
trix metalloproteinases appear to play an important part in
glioma invasion, dissemination, and angio-genesis.8,9 Glio-
mas are themost frequent primary brain tumors in adults, ac-
counting for70%ofall braincancers.10Very recently,data from
the US Nurses’ Health Study II11 showed an increased risk for
thyroid cancer in patients with rosacea. However, that study
was limited to women, and otherwise, to our knowledge, no
substantial reports are available on a potential association be-
tweenrosaceaandmalignantneoplasms.Wehypothesizedthat
sharedpathogenicmechanismsdependenton increasedMMP
activity could provide a link between rosacea and glioma and
we therefore investigated this association in a nationwide
cohort of the Danish population.
Methods
Data Sources and Study Population
TheDanishCivil RegistrationSystemassigns apermanent and
unique 10-digit personal identification number to all citizens
at birth or immigration, which allows for unambiguous link-
age across nationwide registers.12 Moreover, the Danish Civil
RegistrationSystemcontains informationsuchasdateofbirth,
sex, and vital status, and Statistics Denmark records informa-
tion on tax-reported household income.13 The Danish Na-
tionalPatientRegister contains informationonall inpatientand
outpatient (ambulatory) hospital contacts since 1978 accord-
ing to the International Classification of Diseases, Eighth Revi-
sion (ICD-8) before 1994, and the International Statistical Clas-
sificationofDiseases, 10thRevision (ICD-10)wasusedthereafter.
For administrative reasons, the International Classification of
Diseases, Ninth Revision, was never used in Denmark. Hospi-
tal treatment interventions, surgical procedures, andhospital-
administeredpharmacotherapyare codedas treatmentproce-
durecodes.14Since1994,allpharmacy-dispensedprescriptions
in Denmark have been recorded accurately in the Register of
Medicinal Product Statistics, and all drugs are classified ac-
cording to the Anatomical Therapeutical Chemical (ATC)
classification.15 Study approvalwas obtained from theDanish
Data Protection Agency. Review of an ethics committee is not
required for register studies inDenmark.Conductof this study
was in accordance with the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) recom-
mendations.16 Informed consent is not required for adminis-
trativeregistrystudies inDenmark.Alldatawereencryptedand
rendered anonymous when used for research purposes.
All 5 536422 Danish citizens 18 years or older on January
1, 1997,or thesubsequentday they reached18yearsofagewere
included in the cohort. Individualswere followedupuntil De-
cember 31, 2011,migration, adiagnosis of glioma, ordeathdue
to any cause, whichever came first. At baseline, patientswith
prevalent rosacea or glioma were excluded to enable exami-
nationof the temporal relationshipbetweenexposureandout-
comeandtoensureaccurate risk-timeallocation.Patientswith
rosaceawere identified by a hospital (inpatient or outpatient)
diagnosis of rosacea (ICD-8 code 695.3 and ICD-10 code L71)
orwhen theyweredispensed their secondprescriptionof topi-
calmetronidazole (ATCD06BX01),whichever came first.Met-
ronidazole is thepreferred first-line treatment for rosacea and
very infrequently used for other skin conditions in Denmark.
Theprimaryendpointwasahospitaldiagnosisofglioma(ICD-8
code 191 and ICD-10 codes C71, D33, and D43) recorded in the
DanishNational Patient Register. Use of this registry for iden-
tification of cancer and tumor diagnoses has been described
previously with an accuracy of greater than 90%.17 The end
point was decided a priori, and we did not examine the asso-
ciation with other types of cancers.
Statistical Analysis
Data were analyzed from July 14 to August 10, 2015. Baseline
characteristics were presented as frequencies with percent-
ages for categorical variables andmeanswith SDs for continu-
ousvariables. Incidenceratesweresummarizedper10000per-
son-years at risk. Any diagnosis of glioma after the study
started, but before the onset of rosacea, was assigned to the
reference population (n = 5 416 538) to obtain a more accu-
rate allocation of exposure time. We used Poisson regression
distribution models to calculate crude and adjusted inci-
dence rate ratios (IRRs). Given that the causes of glioma are
largelyunknown,we includedage, sex,andsocioeconomicsta-
tus in the adjusted models. Socioeconomic status was calcu-
lated as an index from 0 (lowest) to 4 (highest) based on the
mean gross annual income (standardized by age) during a
5-year period before study inclusion.
For sensitivity analyses,we retrieved informationonpre-
scriptions for tetracycline hydrochloride (ATC J01A),which is
the standard oral medication prescribed for rosacea in Den-
mark, to obtain a reasonably valid estimate of rosacea sever-
ity. Thus, patientswere classified as havingmild disease from
theonsetof rosaceaanduntil they fulfilled thecriteria formod-
erate to severe disease (ie, initiation of oral tetracycline
therapy), if appropriate. In these analyses, patients contrib-
uted risk time in themild rosacea groupuntil they fulfilled the
criteria for moderate to severe rosacea, if appropriate. Pa-
tients were assumed to have predominantly ocular rosacea if
they had claimed a prescription for hypromellose eyedrops
(ATC code S01XA20) that are often used to treat xeropthal-
mia in rosacea, and we identified patients with rhinophyma
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by ICD-10codeL71.1.Weperformedasensitivityanalysiswhere
we used a hospital diagnosis of rosacea (ICD-10 code L71) by
an inpatient or outpatient dermatologist as the exposure vari-
able. In addition, to rule outmisclassification of patientswith
seborrheic dermatitis as having rosacea,we performed sensi-
tivity analyses in which patients with rosacea were excluded
if they had ever (before, during, or after the study period) re-
ceivedtreatmentwithketoconazole inshampooor topical form
(ATC code D01AC08) or topical corticosteroids (ATC code
D07A), which are the typical treatment modalities for sebor-
rheic dermatitis in Denmark.
Model assumptions, including absence of interactions
between model covariates, were tested and found to be valid
unless otherwise indicated. We found a significant interac-
tion between rosacea and sex (P < .001); therefore, overall
and sex-stratified estimates are described. Two-tailed P < .05
was considered statistically significant, and results were
reported with 95% CIs where applicable. All statistical
analyses were performed with the STATA (version 11.0;
StataCorp) and SAS (version 9.2; SAS Institute Inc) statistical
software.
Results
From January 1, 1997, to December 31, 2011, the study popu-
lation consisted of 5 536422Danish citizens 18 years or older.
After excluding 51 512 individuals with prevalent rosacea or
glioma andwith incomplete information onmigration, the fi-
nal cohort consisted of 5 484 910 individuals with a maxi-
mum follow-up of 15 years. The study flowchart is shown in
theFigure, and thebaseline characteristics of the studypopu-
lation are given in Table 1. Of note, 67.3% of the patients with
rosacea were women.
During the study period, a total of 20 934 and 184 pa-
tientswith gliomawere identified among the referencepopu-
lation and the patients with rosacea, respectively. The inci-
dence rate of glioma per 10000 person-years was 3.34 (95%
CI, 3.30-3.39) in the reference population and 4.99 (95% CI,
4.32-5.76) in patients with rosacea, with increased incidence
rates of glioma inmen vswomen among the patientswith ro-
sacea (Table 2).
The crudeandadjusted IRRsof glioma inpatientswith ro-
sacea were 1.49 (95% CI 1.29-1.72), and 1.36 (95% CI 1.18-
1.58), respectively, and stratification for sexyielded similar re-
sults, as shown in Table 3. Among patients with a primary
ICD-10 diagnosis of rosacea by a hospital dermatologist, the
crude and adjusted IRRs of glioma were 1.93 (95% CI 1.23-
3.02) and 1.82 (95% CI 1.16-2.86), respectively. In analyses in
whichpatientswere classified by severity of rosacea basedon
systemic treatmentwithtetracycline, theadjustedIRRsformild
andmoderate to severe rosaceawere 1.43 (95%CI 1.18-1.73) and
1.44 (95% CI 1.14-1.82), respectively (eTable in the Supple-
ment). Themean (SD) time fromonset of rosacea to diagnosis
of gliomawas 4.3 (3.3) and 5.8 (5.6) years, formild and severe
Table 1. Baseline Characteristics of Study Population
Characteristic
Reference
Population
(n = 5 416 538)
Patients
With Rosacea
(n = 68 372)
Age, mean (SD), y 40.8 (19.7) 42.2 (16.5)
Women, No. (%) 2 732 029 (50.4) 45 994 (67.3)
Men, No. (%) 2 684 509 (49.6) 22 378 (32.7)
Socioeconomic status,
mean (SD)a
2.0 (1.4) 2.5 (1.3)
a Calculated as an index from0 (lowest socioeconomic status) to 4 (highest
socioeconomic status) based on themean gross annual income (standardized
by age) during a 5-year period before study inclusion.
Table 2. Incidence Rates of Glioma per 10000 Person-years
Group
Incidence of Glioma
Reference Population Patients With Rosacea
Overall
No. of events 20 934 184
Person-years 62 584 210 369 031.1
Incidence rate (95% CI) 3.34 (3.30-3.39) 4.99 (4.32-5.76)
Women
No. of events 10 877 108
Person-years 31 830 047 251 123.8
Incidence rate (95% CI) 3.42 (3.35-3.48) 4.30 (3.56-5.19)
Men
No. of events 10 057 76
Person-years 30 754 164 117 907.3
Incidence rate (95% CI) 3.27 (3.21-3.33) 6.45 (5.15-8.07)
Figure. Study Flowchart
5 536 422 Danish individuals ≥18 y from 
January 1, 1997, to December 31, 2011
5 484 910 Population suitable for analysis
5 416 538 Reference
population
68 372 Patients with
rosacea
51 512 Excluded
7822 With prevalent rosacea
39 980 With incomplete migration information
3697 With prevalent glioma
13 With prevalent rosacea and prevalent glioma
All Danish citizens 18 years or older
were eligible for the study.
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rosacea, respectively (P = .002). When all patients with rosa-
cea who had ever filled a prescription for treatment of sebor-
rheic dermatitis (ketoconazole [shampoo or topical formula-
tion] or topical corticosteroids)were excluded, the crude and
adjusted IRRs of gliomawere 1.67 (95%CI, 1.27-2.21) and 1.59
(95% CI, 1.20-2.09), respectively. The adjusted IRR of glioma
in patients with rosacea (excluding those with predominant
ocular rosacea as defined by prescription of viscous eye-
drops),was 1.32 (95%CI, 1.12-1.55); in patientswith ocular ro-
sacea, the adjusted IRRwas 1.55 (95%CI, 1.14-2.11). Amongpa-
tients with rhinophyma, we found 3 cases of glioma, and the
adjusted IRR was 1.71 (95% CI, 0.55-5.31; P = .35). Additional
subanalyses are shown in the eTable in the Supplement.
Discussion
Primary Findings
In this nationwide study of the Danish population, we ob-
serveda significantly increased risk for glioma inpatientswith
rosacea. The results remained significant in sensitivity analy-
sesandafter adjustment forpotential confounding factors.No-
tably, the rosacea-associated increased risk for glioma was
greater in men than in women, whereas gliomas and rosacea
were generally more common among women.
Strengths and Limitations
Several strengths and limitations apply to the interpretation
of the present results. The high accuracy of the Danish regis-
ters and the available information on socioeconomic status
allow for large-scale nationwide analyses in which selection
and recall bias are minimized. We used ICD-10 codes and pre-
scriptions of topical metronidazole and tetracycline for rosa-
cea identification and severity classification, respectively.
Tetracycline is used routinely in the treatment of acne vul-
garis and certain infections, but because topical metronida-
zole therapy is not used for these conditions, any misclassifi-
cation related to the use of tetracycline in this specific cohort
is likely negligible. Minocycline is not marketed in Denmark.
However, results of our sensitivity analysis, where the expo-
sure was a hospital diagnosis of rosacea, were generally in
accordance with those of our primary analysis, with the risk
for bias owing to misclassification of patients with rosacea
likely to be low as also indicated by the sensitivity analysis,
with exclusion of patients treated with agents for seborrheic
dermatitis.
Some patients may not seek medical treatment for rosa-
cea. This situation would have led to an underestimation of
rosacea diagnoses and rosacea events in the registries, and
thereby have attenuated the true rosacea-related risk for
glioma. TheDanish population is primarilywhite,whichmay
limit extrapolation toother ethnicitiesbecause rosacea is com-
mon in fair-skinned individuals, and white race is an estab-
lished risk factor for glioma.18,19 The observational nature of
ourstudydoesnotallowestablishmentofcausationandisopen
to the influence of unmeasured confounders. In addition, the
apparent lack of a rosacea severity–dependent risk for glioma
wasmediated by the use of tetracycline, and this notionmay
be supported by the apparent longer time from rosacea onset
to glioma diagnosis in patients with severe rosacea (ie, indi-
viduals treated with tetracyclines).
Although some but not all tetracyclines penetrate the
blood-brain barrier, previous studies20-22 have shown that
tetracycline (in particular, minocycline) inhibits tumorogen-
esis, particularly through antiangiogenic mechanisms involv-
ing inhibition of MMPs. Minocycline has been used experi-
mentally for its antitumor effects; in 1 study in a rodent brain
tumor model,23 local treatment with minocycline contrib-
uted to extended median survival.
Interpretation
Although speculative,mechanismsdependent onMMPsmay
contribute to the linkbetween rosacea and the risk for glioma.
Thus, MMPs, and in particular MMP-9, play a pivotal role in
rosaceaand regulationof the invasivenessofmalignantglioma
cells, and 1 study24 found increased expression of MMP-9 in
tumor tissue specimens from 76% of patients with glioblas-
toma, the most common and aggressive malignant form of
glioma.24-26A role for antimicrobialpeptides in thenaturalhis-
tory of glioma has not been reported, but the apparent joint
contributionofMMPs to thepathophysiologicmechanismsof
the 2 diseases, and, for example, recent evidence indicating
activation of interleukin 17–dependent inflammatory path-
ways in rosacea and glioma, clearly suggest that such shared
pathophysiologic mechanisms may contribute to the epide-
miologic associationobserved in thepresent study.27-29 In ad-
dition, studies have suggested that theHLAclass II histocom-
patibilityantigen,DRαchain (HLA-DRA), isaprominentgenetic
component in rosacea, andHLA-DRAgeneexpressionalso ap-
pears to be important for interferon-γ expression and respon-
sivity in glioblastomamultiforme.30-32
Conclusions
Rosacea is associated with a significantly increased risk for
glioma. This associationmay bemediated, in part, bymecha-
nisms dependent on MMPs. Increased focus on neurologic
symptoms (eg, headaches, memory loss, seizures, loss of
muscle control, visual symptoms, dysarthria, cognitive de-
cline, and personality changes) in patients with rosacea and
timely referral to relevant specialists may be warranted.
Table 3. IRRs of Glioma in PatientsWith Rosacea
Patients With Rosacea Crude IRR (95% CI) P Valuea Adjusted IRR (95% CI)b P Valuea
Overall 1.49 (1.29-1.72) <.001 1.36 (1.18-1.58) <.001
Women 1.26 (1.04-1.52) .02 1.27 (1.05-1.54) .01
Men 1.97 (1.57-2.47) <.001 1.47 (1.17-1.84) <.001
Abbreviation: IRR, incidence rate
ratio.
a Calculated using the 2-tailed test.
bAdjusted for age, sex, and
socioeconomic status.
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